ImmunoGen Inc

ImmunoGen — JP Morgan Healthcare Conference 2023

31 slides from ImmunoGen's conference presentation, Jan 9, 2023

  1. Slide 1: Target a Better Now - JP Morgan Healthcare Conference

    Slide 1: Target a Better Now - JP Morgan Healthcare Conference

    1 TARGET A BETTER NOW JP Morgan Healthcare Conference January 9 - 12, 2023 Nasdaq: IMGN

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    2 FORWARD - LOOKING STATEMENTS This presentation includes forward - looking statements regarding ImmunoGen’s current expectations related to : the commercialization of ELAHERE, the design and potential success of 420 study, pivekimab sunirine, IMGC 936 , and IMGN 151 preclinical and clinical studies

  3. Slide 3: About ImmunoGen: A Fully-Integrated Oncology Company

    Slide 3: About ImmunoGen: A Fully-Integrated Oncology Company

    3 ABOUT IMMUNOGEN A FULLY - INTEGRATED ONCOLOGY COMPANY A Leader in the Research and Development of ADCs with 40+ Years of Expertise Clinical Pipeline of Novel ADCs for Solid Tumors and Hematologic Malignancies TARGET A BETTER NOW ADC: antibody - drug conjugate ImmunoGen technology has produced thre

  4. Slide 4: ELAHERE: First and Only ADC Approved in Ovarian Cancer

    Slide 4: ELAHERE: First and Only ADC Approved in Ovarian Cancer

    4 ELAHERE: FIRST AND ONLY ADC APPROVED IN OVARIAN CANCER • ELAHERE granted accelerated approval by FDA for the treatment of PROC on November 14 • Inclusion of ELAHERE monotherapy and in combination with bevacizumab in NCCN guidelines and compendium • Completed enrollment in MIRASOL with top - line d

  5. Slide 5: Strategic Priorities

    Slide 5: Strategic Priorities

    5 STRATEGIC PRIORITIES DEVELOPING AND COMMERCIALIZING ADCs TO IMPROVE OUTCOMES FOR CANCER PATIENTS ADAM9: ADAM metallopeptidase domain 9; ADC: antibody - drug conjugate; AML: acute myeloid leukemia; BPDCN: blastic plasmacytoid dendritic cell neoplasm; FR  : folate receptor alpha FURTHER EXPAND capa

  6. Slide 6: ELAHERE: Now Approved in the US

    Slide 6: ELAHERE: Now Approved in the US

    6 ELAHERE is indicated for the treatment of adult patients with folate receptor - alpha (FR  ) positive, platinum - resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. This indication is approved under acceler

  7. Slide 7: ELAHERE Launch Imperatives

    Slide 7: ELAHERE Launch Imperatives

    7 ELAHERE LAUNCH IMPERATIVES FR  : folate receptor alpha Redefine expectations for positive treatment outcomes in ovarian cancer with ELAHERE Ensure a positive physician experience based on education and guidance for patient management Seek broad payer access and reimbursement and deliver a seamles

  8. Slide 8: ELAHERE Commercial Update

    Slide 8: ELAHERE Commercial Update

    8 ELAHERE COMMERCIAL UPDATE STRONG PROGRESS OVER FIRST SEVEN WEEKS Redefine expectations for positive treatment outcomes in ovarian cancer with ELAHERE Ensure a positive physician experience based on education and guidance for patient management Seek broad payer access and reimbursement and deliver

  9. Slide 9: Move into Platinum-Sensitive Disease and Become Combination Agent of Choice

    Slide 9: Move into Platinum-Sensitive Disease and Become Combination Agent of Choice

    9 Goal: Move into Platinum - Sensitive Disease and Become the Combination Agent of Choice in Ovarian Cancer • Single - arm Phase 2 trial for mirvetuximab in FR α - high patients with PSOC • Enrollment ongoing • ORR data by year - end 2023; potential for label expansion in 2024 MIRVETUXIMAB IN DEVELO

  10. Slide 10: Current Label and Development Program Targets High Proportion of Ovarian Cancer Patients

    Slide 10: Current Label and Development Program Targets High Proportion of Ovarian Cancer Patients

    10 5,200 7,000 7,400 10,600 11,400 14,300 CURRENT LABEL AND DEVELOPMENT PROGRAM TARGETS HIGH PROPORTION OF OVARIAN CANCER PATIENTS POTENTIAL ELAHERE - ELIGIBLE FR  - POSTIVE PATIENTS (U.S.) MONOTHERAPY 2L - 4L Platinum - Resistant COMBINATION Bev - Combo in 2L+ Platinum - Resistant MONOTHERAPY 3L+

  11. Slide 11: ELAHERE Global Commercialization Strategy

    Slide 11: ELAHERE Global Commercialization Strategy

    11 ELAHERE GLOBAL COMMERCIALIZATION STRATEGY • Partnership accelerates development path for ELAHERE in Greater China given Huadong’s regional oncology expertise • ImmunoGen received a $40M upfront payment and is eligible to receive development, regulatory, and commercial milestone payments in aggreg

  12. Slide 12: Pivekimab Sunirine (IMGN632)

    Slide 12: Pivekimab Sunirine (IMGN632)

    12 PIVEKIMAB SUNIRINE (IMGN632) DESIGNED TO TARGET MULTIPLE CD123+ HEMATOLOGIC MALIGNANCIES 1 ASH 2018 Oral Presentation; Daver , N., et al. ASH 2019 Oral Presentation; Daver , N., et al. 2 ASH 2020 Oral Presentation; Pemmaraju, N., et al. ADC: antibody drug conjugate; AML: acute myeloid leukemia; B

  13. Slide 13: BPDCN Is a Rare and Aggressive Hematologic Malignancy

    Slide 13: BPDCN Is a Rare and Aggressive Hematologic Malignancy

    13 INTENSIVE CHEMO OR TARGETED THERAPY DIAGNOSIS STEM CELL TRANSPLANT CHEMO OR TARGETED THERAPY Select cases CURRENTLY APPROVED THERAPY REQUIRES INPATIENT HOSPITALIZATION AND IS ASSOCIATED WITH SIGNIFICANT TOXICITIES URGENT NEED BPDCN IS A RARE AND AGGRESSIVE HEMATOLOGIC MALIGNANCY ~ 500 TO ~1,000 N

  14. Slide 14: Pivekimab in Frontline BPDCN

    Slide 14: Pivekimab in Frontline BPDCN

    14 In the first 10 patients in the pivotal cohort: • 4 de novo BPDCN and 6 with PCHM • 2 of 4 de novo patients achieved CR/ CRc • 4 of 6 PCHM patients achieved CR/ CRc / CRh — Fifth PCHM patient achieved CRi , and a sixth was able to bridge to transplant PIVEKIMAB IN FRONTLINE BPDCN EVALUATING POTEN

  15. Slide 15: AML Is an Aggressive Hematologic Malignancy

    Slide 15: AML Is an Aggressive Hematologic Malignancy

    15 AML IS AN AGGRESSIVE HEMATOLOGIC MALIGNANCY ~20,000 PEOPLE DIAGNOSED WITH AML AND ~11,000 DIE ANNUALLY IN THE U.S. 1 FIT PATIENTS 2 Approximately half of patients are “fit” enough to undergo intensive chemotherapy and transplant with curative intent Median survival: 2 - 4 years UNFIT PATIENTS 2 A

  16. Slide 16: Pivekimab in AML

    Slide 16: Pivekimab in AML

    16 1 ASH 2022 Oral Presentation Abstract #62; Daver , N., et al. AML: acute myeloid leukemia; ASH: American Society of Hematology; CCR: composite complete remission rate includes CR + CRh + CRp + CRi ; COMBO: combination; FLT3: Fms Related Receptor Tyrosine Kinase 3; ORR: objective response rate; R/

  17. Slide 17: IMGC936: First-in-Class ADAM9-Targeting ADC

    Slide 17: IMGC936: First-in-Class ADAM9-Targeting ADC

    17 IMGC936 FIRST - IN - CLASS ADAM9 - TARGETING ADC KEY ATTRIBUTES • ADAM9 is overexpressed in multiple solid tumors (e.g., non - small cell lung, gastric, pancreatic, triple - negative breast, and colorectal) 1 with low levels of expression in normal tissue • IMGC936 comprised of a high - affinity

  18. Slide 18: IMGN151: Next-Generation FRα-Targeting ADC

    Slide 18: IMGN151: Next-Generation FRα-Targeting ADC

    18 1 AACR 2020 Poster; Ab, O., et al. ADC: antibody - drug conjugate; FPI: first patient in; FR  : folate receptor alpha : folate receptor alpha; 18 KEY ATTRIBUTES • Next - generation anti - FRα ADC designed to target tumors with a broad range of FRα - expression (e.g., ovarian, endometrial, triple

  19. Slide 19: Pipeline Expansion and Out-Licensing Strategy

    Slide 19: Pipeline Expansion and Out-Licensing Strategy

    19 PIPELINE EXPANSION AND OUT - LICENSING STRATEGY LEVERAGE IP PORTFOLIO AND EXPERTISE TO CREATE VALUE INDEPENDENTLY AND VIA PARTNERSHIPS Development and commercialization of ELAHERE in Greater China Global co - development and co - commercialization of IMGC936 IP, KNOW - HOW, AND RESEARCH CAPABILIT

  20. Slide 20: Value Creation Opportunities in 2023

    Slide 20: Value Creation Opportunities in 2023

    20 VALUE CREATION OPPORTUNITIES IN 2023 ESTABLISH ELAHERE AS THE STANDARD OF CARE IN FR  POSITIVE PATIENTS • Progress pivotal CADENZA study in frontline BPDCN ADAM: a disintegrin and metalloproteinase; ADC: antibody - drug conjugate; AML: acute myeloid leukemia; BPDCN: blastic plasmacytoid dendriti

  21. Slide 21: Appendix

    Slide 21: Appendix

    21 TARGET A BETTER NOW APPENDIX

  22. Slide 22: A Leader in ADC Innovation

    Slide 22: A Leader in ADC Innovation

    22 A LEADER IN ADC INNOVATION 40+ YEARS OF KNOW - HOW AND RICH PORTFOLIO OF PLATFORM IP • Multiple mechanisms of action: • Tubulin - acting (DM1, DM4, DM21) • DNA - acting IGNs • Camptothecins • Bystander activity for heterogeneously expressed targets • Cleavable • Non - cleavable • Multiple methods

  23. Slide 23: ImmunoGen ADCs At-A-Glance

    Slide 23: ImmunoGen ADCs At-A-Glance

    23 IMMUNOGEN ADCs AT - A - GLANCE MIRVETUXIMAB SORAVTANSINE Folate receptor alpha - targeting ADC PIVEKIMAB SUNIRINE (IMGN632) CD123 - targeting ADC IMGC936 ADAM9 - targeting ADC IMGN151 Folate receptor alpha - targeting ADC ANTIBODY: Hu manized monoclonal antibody which selectively binds to FR α PA

  24. Slide 24: A Commitment to Targeted Medicines

    Slide 24: A Commitment to Targeted Medicines

    24 A COMMITMENT TO TARGETED MEDICINES Ovarian Cancer Hematologic Malignancies Other Solid Tumors ADAM9: ADAM metallopeptidase domain 9; ADC: antibody - drug conjugate; AML: acute myeloid leukemia; BPDCN: blastic plasmacytoid dendritic cell neoplasm; FR  : folate receptor alpha; NSCLC: non – small c

  25. Slide 25: SORAYA: Positive Results

    Slide 25: SORAYA: Positive Results

    25 SORAYA: POSITIVE RESULTS 1 Source: Prescribing information; 2 Data on file. *95% exact confidence interval is estimated by Clopper - Pearson method (Clopper - Pearson exact CI). KEY EFFICACY ENDPOINTS ORR% BY INVESTIGATOR 1 0% 10% 20% 30% 40% 50% 60% DOR BY INVESTIGATOR 1 33 responders • 5; 4.8%

  26. Slide 26: Randomized Trial for Mirvetuximab in Platinum-Resistant Ovarian Cancer

    Slide 26: Randomized Trial for Mirvetuximab in Platinum-Resistant Ovarian Cancer

    CONFIDENTIAL 26 Mirvetuximab PHASE 3 RANDOMIZED TRIAL FOR MIRVETUXIMAB IN FR α - HIGH PATIENTS WITH PLATINUM - RESISTANT OVARIAN CANCER *Eligibility criterion different than SORAYA BICR: blinded independent central review; BRCA: BReast CAncer gene; FR α : folate receptor alpha; IC: investigator’s ch

  27. Slide 27: Mirvetuximab + Bevacizumab Maintenance in Platinum-Sensitive Ovarian Cancer

    Slide 27: Mirvetuximab + Bevacizumab Maintenance in Platinum-Sensitive Ovarian Cancer

    CONFIDENTIAL 27 RANDOMIZED PHASE 3 TRIAL FOR MIRVETUXIMAB + BEVACIZUMAB MAINTENANCE IN FR α - HIGH PLATINUM - SENSITIVE OVARIAN CANCER PRIMARY ENDPOINT PFS SECONDARY ENDPOINTS OS, DOR ENROLLMENT AND KEY ELIGIBILITY 438 patients Platinum - sensitive ovarian cancer 1 prior platinum treatment Prior PAR

  28. Slide 28: Single-Arm Trial for Mirvetuximab in Platinum-Sensitive Ovarian Cancer

    Slide 28: Single-Arm Trial for Mirvetuximab in Platinum-Sensitive Ovarian Cancer

    CONFIDENTIAL 28 SINGLE - ARM TRIAL FOR MIRVETUXIMAB IN FR α - HIGH PATIENTS WITH PLATINUM - SENSITIVE OVARIAN CANCER PRIMARY ENDPOINT ORR by Investigator SECONDARY ENDPOINT DOR by Investigator ENROLLMENT AND KEY ELIGIBILITY ~75 patients Platinum - sensitive ovarian cancer 2 or more prior systemic tr

  29. Slide 29: Mirvetuximab + Carboplatin Trial in Platinum-Sensitive Ovarian Cancer

    Slide 29: Mirvetuximab + Carboplatin Trial in Platinum-Sensitive Ovarian Cancer

    CONFIDENTIAL 29 SINGLE - ARM PHASE 2 TRIAL OF MIRVETUXIMAB + CARBOPLATIN FOLLOWED BY MIRVETUXIMAB CONTINUATION IN FR α - LOW, MEDIUM, AND HIGH PATIENTS WITH PLATINUM - SENSITIVE OVARIAN CANCER PRIMARY ENDPOINT ORR by Investigator SECONDARY ENDPOINTS DOR, PFS ENROLLMENT AND KEY ELIGIBILITY ~110 patie

  30. Slide 30: ELAHERE Label Expansion Opportunities

    Slide 30: ELAHERE Label Expansion Opportunities

    30 ELAHERE LABEL EXPANSION OPPORTUNITIES GOAL TO MOVE INTO PLATINUM - SENSITIVE DISEASE AND BECOME THE COMBINATION AGENT OF CHOICE IN OVARIAN CANCER 89% ORR ACROSS ALL LEVELS OF FR α EXPRESSION n= 9 64% ORR FR α - HIGH RECURRENT OVARIAN CANCER n= 11 MIRVETUXIMAB + BEVACIZUMAB 2 MIRVETUXIMAB + CARBOP

  31. Slide 31: Significant Growth Expected for Ovarian Cancer Market

    Slide 31: Significant Growth Expected for Ovarian Cancer Market

    31 SIGNIFICANT GROWTH EXPECTED FOR OVARIAN CANCER MARKET $2.1 $6.5 2023 2028 U.S. Ovarian Cancer Market Sales ($ USD Billions) +25% CAGR Approval and launch of targeted therapies anticipated to drive majority of growth $4.4 $10.5 2023 2028 Global Ovarian Cancer Market Sales ($ USD Billions) +19% CAG

Source: SEC EDGAR · 8-K filed Jan 9, 2023

More decks from ImmunoGen Inc